Durham-based Atsena Therapeutics has raised $150 million to advance gene therapies for preventing or reversing types of ...

Liquidia's collaboration with Sandoz and development of new products like L606 show promise. Learn why LQDA stock is a Hold.

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

United Therapeutics (UTHR) announced that ten posters and presentations across its commercial and development portfolio will be presented at ...

StockNews.com initiated coverage on shares of Revance Therapeutics (NASDAQ:RVNC – Free Report) in a research note published ...

The City of Kannapolis’ free West Avenue Express shuttle service will begin running weekends only starting Friday, April 4.

Edgecombe, Beaufort and Nash leaders recently described how they're working to cut opioid overdoses, and they all went to the source.

Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of ...

Jaguar Health, Inc. (NASDAQ:JAGX) (”Jaguar” or “the Company”), today announced the closing of its previously announced private placement.

The field of gene editing recently got a major boost from Massachusetts-based Beam Therapeutics, and the company’s Durham ...

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2024 Earnings Call Transcript March 13, 2025 Seres Therapeutics, Inc. beats ...

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Akebia Therapeutics Inc. (AKBA) on Thursday reported a fourth-quarter loss of $22.8 million, after reporting a profit in the same period a year earlier.